Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens

European Journal of Haematology

Volumn 66, Issue 2, 2001, Pages 94-99

  Avilés, Agustin ^a,b   Cleto, Sergio ^a   Huerta Guzmán, Judith ^a   Neri, Natividad ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b NONE   (Mexico)

Author keywords

Intensive chemotherapy; Interferon; Maintenance therapy; Malignant lymphoma; Poor prognostic factors

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; TUMOR VOLUME;

ACTUARIAL ANALYSIS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; INTERFERON ALFA-2B; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; VINCRISTINE;

EID: 0035121441     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00272.x     Document Type: Article

References (22)

1. A predictive model for aggressive non-Hodgkin's lymphoma
2. Intensive brief chemotherapy with hematopoietic growth factors as hematologfical support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma
3. Epirubicin (CEOP-BLEO) versus idaurubicin (CIOP-BLEO) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Dose escalation studies
4. High dose chemotherapy in the treatment of poor prognosis malignant lymphoma
5. BEAM chemotherapy and autologous hematopoietic progenitor cell transplantation as first line therapy for high risk patients with diffuse large cell lymphoma
6. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
7. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma. Pattern of failure and implications for involved-field radiotherapy
8. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma. Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group
9. Clinical impact of chemotherapy dose escalation in patients with hematological malignancies and solid tumors
10. The role of maintenance therapy in the management of diffuse large cell lymphoma
11. Maintenance therapy with inteferon alfa 2b improves outcome in aggressive maligant lymphoma
12. Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma
13. Non parametric estimation from incomplete observation
14. GM-CSF instead of hematological support during high-dose chemotherapy for refractory malignant lymphoma
15. Results of high dose therapy and autologous bone marrow stem cell transplantatioin during remission in poor risk intermediate and high-grade lymphoma International Index high and high-intermediate
16. Benefit for autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma
17. Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma
18. Biotherapy in clinical practice
19. Biological response modifiers in non-Hodgkin's lymphoma
20. Interferon and malignant disease. How does it work and why doesn't it always
21. The role of interferon as maintenance therapy in malignant lymphoma
22. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin 2 in malignant lymphoma